Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

aflibercept

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

- PMLiVE

Roche’s Evrysdi shows continued improvement in children with spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies

Bayer symbol

Bayer and BlueRock announce positive early-stage results for Parkinson’s cell therapy

The progressive neurological disorder affects around ten million people worldwide

- PMLiVE

Roche’s fixed-duration lymphoma treatment granted FDA accelerated approval

Globally around 160,000 people are diagnosed with non-Hodgkin's lymphoma each year

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation

Bayer symbol

Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer

More than 47,000 new cases of prostate cancer are diagnosed every year in England

- PMLiVE

Roche reports positive results for drug for relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine

The biologic was shown to significantly improve uncontrolled prurigo nodularis symptoms

- PMLiVE

Roche reports positive phase 3 data for Tecentriq combination in liver cancer

More than 900,000 people are diagnosed with the disease globally each year

regeneron headquarters

Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies

Sonoma will receive $75m upfront and will be eligible for a $45m milestone payment

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children

Dupixent is now the first and only targeted medicine in the EU for this patient population

- PMLiVE

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

If approved, the test could streamline the journey to diagnosis for more patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links